Quantcast
Last updated on April 18, 2014 at 9:07 EDT

Latest Blood disorders Stories

2012-05-31 01:19:22

-SMIP-016 is a promising experimental drug that kills chronic leukemia cells. -The drug targets a protein called CD37, but it wasn´t known how this kills leukemia cells. -This study showed unexpectedly that CD37 helps regulate both cell-death and cell-survival signals, explaining how the drug works and how it might be improved. A new study has identified a life-and-death signaling role for a molecule on the surface of the immune cells involved in the most common form of chronic...

Synthetic Platelets Developed By UC Santa Barbara Researchers
2012-05-30 11:24:54

Synthetic platelets have been developed by UC Santa Barbara researchers, in collaboration with researchers at Scripps Research Institute and Sanford-Burnham Institute in La Jolla, Calif. Their findings are published in the journal Advanced Materials in a paper titled "Platelet Mimetic Particles for Targeting Thrombi in Flowing Blood." Platelets are the components of blood that allow it to prevent excessive bleeding and to heal wounds. The unique physical and biochemical properties of...

2012-05-29 10:24:27

SEATTLE, May 29, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) will host an investor and analyst meeting to discuss unmet medical needs and targeted agents in myelofibrosis and high-risk myelodysplastic syndrome/acute myeloid leukemia, including data from pacritinib, the product candidate that CTI has agreed to acquire, and CTI's product candidate tosedostat. The event will take place on Sunday, June 3, 2012 in Chicago, Illinois. The American Society of Clinical...

2012-05-29 09:06:40

The fight against cancer is not won in a single battle: Long after a cancer has been beaten into remission, it can return. The reason for this is under debate, and much is unclear. New research led by Weizmann Institute scientists shows that, at least for one type of blood cancer, the source of cancer recurrence is in a set of cells that do not proliferate as quickly as regular cancer cells, and thus able to survive chemotherapy. The findings, which appeared today in the journal Blood, have...

2012-05-29 02:26:50

UNION CITY, Calif., May 29, 2012 /PRNewswire/ -- Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood analysis systems, announced today that Clint Severson, chairman and chief executive officer , will present at the Jefferies 2012 Global Healthcare Conference on Tuesday, June 5, 2012 at 9:00 a.m. ET. The conference will be held at the Grand Hyatt in New York City. About Abaxis Abaxis develops, manufactures, markets and sells portable...

2012-05-24 10:24:23

WASHINGTON, May 24, 2012 /PRNewswire-USNewswire/ -- Today the Senate passed S. 3187, its version of the Prescription Drug User Fee Act (PDUFA) legislation including important provisions to mitigate drug shortages, most notably mandating an early warning system for manufacturers. ASH is the world's largest professional society concerned with the causes and treatment of blood disorders, representing more than 14,000 members who specialize in blood cancers such as leukemia, lymphoma,...

2012-05-24 10:24:01

WHITE PLAINS, N.Y., May 24, 2012 /PRNewswire/ -- Making every cent count, students at Walter Johnson High School in Bethesda, Md., raised an incredible $59,029.54 through Pennies for Patients, making them the top fundraiser nationwide in The Leukemia & Lymphoma Society's School & Youth Programs. Across the United States and Canada, 27,482 schools - more than 15.8 million students from kindergarten to high school - participated in the programs during the 2011-12 school year, raising a...

2012-05-24 06:28:41

SAN DIEGO, May 24, 2012 /PRNewswire/ -- Sangart, Inc., a global biopharmaceutical company dedicated to developing and commercializing targeted rescue therapies for patients in acute ischemic crisis, today announced that it recently received $50 million in additional equity funding from existing investor, Leucadia National Corporation. This funding was made upon the exercise of Series G preferred stock warrants previously held by Leucadia and brings the total funding raised by the company...

2012-05-22 02:26:24

SUNNYVALE, Calif., May 22, 2012 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that clinical abstracts on Bruton's Tyrosine Kinase inhibitor, ibrutinib (formerly, PCI-32765) have been selected for oral presentations at the 17th Congress of the European Hematology Association (EHA), June 14-17, 2012 in Amsterdam, The Netherlands. The update on data presented specifically includes: 1) updated safety and efficacy data, including progression free survival, from the...

2012-05-21 02:24:45

AMSTERDAM, May 21, 2012 /PRNewswire/ -- 3rd Invitation to 17th Congress of EHA - European Hematology Association The Board of the European Hematology Association (EHA) has the pleasure to cordially invite you, as a member of the press, to the 17th Congress of EHA. More than 9,000 participants from around the world are expected at the upcoming Congress at the RAI Congress Center in Amsterdam from June 14-17, 2012. About the EHA Annual Congress: The...